Oral mucositis: A challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: Diagnosis and management of mucositis

被引:118
作者
Scully, C
Epstein, J
Sonis, S
机构
[1] UCL, Int Ctr Excellence Dent, World Hlth Org Collaborating Ctr Oral Hlth Disabi, London WC1X 8LD, England
[2] UCL, Eastman Dent Inst Oral Hlth Care Sci, World Hlth Org Collaborating Ctr Oral Hlth Disabi, London WC1X 8LD, England
[3] Univ Illinois, Dept Oral Med & Diagnost Sci, Coll Dent, Coll Med,Chicago Canc Ctr, Chicago, IL USA
[4] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Brigham & Womens Hosp,Div Oral Med, Boston, MA 02115 USA
[5] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Brigham & Womens Hosp,Div Oral & Maxillofacial Su, Boston, MA 02115 USA
[6] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Brigham & Womens Hosp,Div Dent, Boston, MA 02115 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2004年 / 26卷 / 01期
关键词
cancer; chemotherapy; mucositis; oral; radiotherapy;
D O I
10.1002/hed.10326
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Oral mucositis is a common sequel of radiotherapy, chemotherapy, and radiochemotherapy in patients with cancer or patients requiring hemopoietic stem cell transplants. Mucositis has a direct and significant impact on the duration of disease remission and cure rates, because it is a treatment-limiting toxicity. Mucositis also affects survival because of the risk of infection and has a significant impact on quality of life and cost of care. Methods. This article reviews publications on the diagnosis and management of oral mucositis accessible from a MEDLINE search using as key words mucositis, radiotherapy, chemotherapy, hemopoietic stem, cell transplant, and oral. Conclusions. Conventional care of patients with mucositis is currently essentially palliative, with good oral hygiene, narcotic analgesics, and topical palliative mouth rinses. (C) 2004 Wiley Periodicals, Inc.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 101 条
[1]   COMPREHENSIVE CRITERIA FOR ASSESSING THERAPY-INDUCED TOXICITY [J].
AJANI, JA ;
WELCH, SR ;
RABER, MN ;
FIELDS, WS ;
KRAKOFF, IH .
CANCER INVESTIGATION, 1990, 8 (02) :147-159
[2]   SYMPTOMATIC ACUTE MUCOSITIS CAN BE MINIMIZED OR PROPHYLAXED BY THE COMBINATION OF SUCRALFATE AND FLUCONAZOLE [J].
ALLISON, RR ;
VONGTAMA, V ;
VAUGHAN, J ;
SHIN, KH .
CANCER INVESTIGATION, 1995, 13 (01) :16-22
[3]   THE EFFECTS OF SUCRALFATE SUSPENSION AND DIPHENHYDRAMINE SYRUP PLUS KAOLIN-PECTIN ON RADIOTHERAPY-INDUCED MUCOSITIS [J].
BARKER, G ;
LOFTUS, L ;
CUDDY, P ;
BARKER, B .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1991, 71 (03) :288-293
[4]   PHASE-II STUDY OF A 5-FLUOROURACIL, TENIPOSIDE AND MITOMYCIN-C COMBINATION CHEMOTHERAPY IN ADVANCED COLORECTAL CARCINOMAS [J].
BECOUARN, Y ;
CALABET, J ;
BRUNET, R .
TUMORI JOURNAL, 1988, 74 (01) :75-77
[5]   ORAL INFECTIONS AND SEPTICEMIA IN IMMUNOCOMPROMISED PATIENTS WITH HEMATOLOGIC MALIGNANCIES [J].
BERGMANN, OJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (10) :2105-2109
[6]   ALTERATIONS IN ORAL MICROFLORA AND PATHOGENESIS OF ACUTE ORAL INFECTIONS DURING REMISSION-INDUCTION THERAPY IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA [J].
BERGMANN, OJ .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (03) :355-366
[7]   ORAL INFECTIONS AND FEVER IN IMMUNOCOMPROMISED PATIENTS WITH HEMATOLOGIC MALIGNANCIES [J].
BERGMANN, OJ .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (03) :207-213
[8]  
Berkowitz R J, 1987, Pediatr Dent, V9, P105
[9]   Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview [J].
Blijlevens, NMA ;
Donnelly, JP ;
De Pauw, BE .
BONE MARROW TRANSPLANTATION, 2000, 25 (12) :1269-1278
[10]   EFFECT OF PROPHYLACTIC MEASURES ON MICROBIAL FLORA OF PATIENTS IN PROTECTED ENVIRONMENT UNITS [J].
BODEY, GP ;
ROSENBAUM, B .
MEDICINE, 1974, 53 (03) :209-228